目的 探討芪藶強(qiáng)心膠囊聯(lián)合尼可地爾治療冠心病心絞痛患者的臨床效果。方法 選取2016年1月-2017年5月三門峽市中醫(yī)院收治的冠心病心絞痛患者142例，隨機(jī)分成對照組（71例）和治療組（71例）。對照組患者口服尼可地爾片，1片/次，3次/d；治療組患者在對照組用藥基礎(chǔ)上口服芪藶強(qiáng)心膠囊，4粒/次，3次/d。兩組患者均經(jīng)過2個月治療。觀察兩組患者臨床療效和心電圖療效，同時比較治療前后兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時間、運動平板試驗、CD105和基質(zhì)金屬蛋白酶-9（MMP-9）水平及不良反應(yīng)。結(jié)果 治療后，對照組臨床有效率為81.69%，心電圖療效為85.92%，均分別顯著低于治療組的94.37%和97.18%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時間均顯著下降（P<0.05），且治療組患者心絞痛發(fā)作次數(shù)和持續(xù)時間明顯少于對照組（P<0.05）。治療后，兩組患者平均運動時間和運動負(fù)荷量顯著升高（P<0.05），運動ST段壓低顯著降低（P<0.05），且治療后治療組患者運動平板試驗結(jié)果明顯好于對照組（P<0.05）。治療后，兩組患者CD105水平和MMP-9水平均顯著降低（P<0.05），且治療組患者CD105和MMP-9水平明顯低于對照組（P<0.05）。治療期間，對照組患者不良反應(yīng)發(fā)生率為16.90%，顯著高于治療組的4.23%，兩組患者比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合尼可地爾治療冠心病心絞痛療效明顯，安全性高，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Qili Qiangxin Capsules combined with nicorandil in treatment of angina pectoris of coronary heart disease. Methods Patients (142 cases) with angina pectoris of coronary heart disease in the Chinese Medicine Hospital of Sanmenxia City from January 2016 to May 2017 were randomly divided into control (71 cases) and treatment (71 cases) groups. Patients in the control group were po administered with Nicorandil Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical and electrocardiographic efficacy was evaluated, and the frequency and duration of angina pectoris, the treadmill exercise test, the CD105 and MMP-9 Levels, adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.69%, and the electrocardiographic efficacy was 85.92%, which were significantly lower than 94.37% and 97.18% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups was significantly decreased (P<0.05), and the frequency and duration of angina pectoris in the treatment group after treatment was significantly less than that in the control group (P<0.05). After treatment, the average exercise time and exercise load in two groups was significantly increased (P<0.05), the exercise ST depression was significantly decreased (P<0.05), and the treadmill exercise test result in the treatment group after treatment was significantly better than those in the control group (P<0.05). After treatment, the CD105 and MMP-9 levels in two groups were significantly decreased (P<0.05), and the CD105 and MMP-9 levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the control group was 16.90%, which was significantly higher than 4.23% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Qili Qiangxin Capsules combined with nicorandil in treatment of angina pectoris of coronary heart disease has obvious curative effect and high safety, which has a certain clinical application value.